Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2021 - 12 - 13 save search
First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Published: 2021-12-13 (Crawled : 13:27) - alteritytherapeutics.com
ATHE | $2.13 10K
|
Health Technology
|
| O: 0.24%
H: 3.2%
C: 0.42%
ath434 phase 2 trial authorization
Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
SNDX | $21.13 0.81% 250K
|
Health Technology
|
| O: -6.48%
H: 18.59%
C: 10.02%
gment-101 als 613 trial phase 1 positive
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual MeetingPreliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
BPTH 3 d | $2.695 -7.7% 260K
|
Health Technology
|
| O: -9.01%
H: 0.0%
C: 0.0%
ema phase 2 ongoing risk aml
STAG Industrial Publishes Inaugural Sustainability Report
Published: 2021-12-13 (Crawled : 22:00) - stagindustrial.com
STAG | $35.56 0.62% 440K
|
Finance
|
| O: 2.86%
H: 0.44%
C: -1.16%
trial
Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System
Published: 2021-12-13 (Crawled : 22:00) - poseida.com
PSTX | $2.175 0.93% 170K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: -5.5%
als car-t trials trial clinical trials t-cell
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
GILD | $67.25 0.45% 2M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
zuma-12 yescarta treatment risk t-cell
Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
KROS | $56.09 0.56% 230K
|
Health Technology
|
| O: -9.67%
H: 1.03%
C: 0.73%
ker-050 ema trial therapeutics preclinical results pre-clinical
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $170.19 1.37% 1.6M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.22 1.84% 370K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
CNH Industrial recognized with prestigious double ‘A’ score for global climate and water stewardship by CDP
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
CNHI | $11.56 0.52% 9.9M
|
Producer Manufacturing
|
| O: -0.48%
H: 0.0%
C: 0.0%
trial
Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
AQST | $4.315 -1.48% 1M
|
Health Technology
|
| O: -3.23%
H: 0.0%
C: 0.0%
aqst-109 drug trial therapeutics epinephrine submission
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
GALT | $3.425 11.93% 130K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
phase 2 trial therapeutics immunotherapy potential therapy cancer
Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
NKTX | $7.55 2.17% 290K
|
Health Technology
|
| O: -9.32%
H: 8.1%
C: -2.59%
nkx019 trial
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.47 2.06% 850K
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
ema als trials trial therapeutics phase 1 positive
Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
VIRX | $0.88 33K
|
Manufacturing
|
| O: -2.86%
H: 0.0%
C: 0.0%
phase 1b therapeutics presentation phase 1 positive phase 2b
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
AGIO | $31.645 4.75% 350K
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
transfusion
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
KURA | News | $19.04 4.67% 420K
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
phase 2 results t-cell
REV GROUP® COMPANY DELIVERS ELECTRIC AMBULANCE TO HAMAD MEDICAL CORPORATION IN QATAR FOR OPERATIONAL TRIAL
Published: 2021-12-13 (Crawled : 19:00) - revgroup.com
REVG 4 | $21.83 1.16% 790K
|
Consumer Durables
|
| O: -2.18%
H: 2.29%
C: -1.48%
group liver trial
CareDx Partners with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Organization in Launching Prospective, Multi-Center Pediatric Kidney Transplant Study
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
CDNA | $8.375 2.51% 180K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
als renal trials trial kidney
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
ABBV | News | $170.19 1.37% 1.6M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.22 1.84% 370K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 positive bioscience results
Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 17:00) - biospace.com/
RFL 4 | $1.7 -2.3% 7.5K
|
Finance
|
| O: -2.82%
H: 0.0%
C: 0.0%
cpi-613 613 ema phase 2 als trial
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.